Efficacy of FemiScan Pelvic Floor Therapy for the Treatment of Anal Incontinence

This study was undertaken to document the effect of FemiScan on anal incontinence symptoms of women who completed a physician–supervised program. Methods Women referred for treatment of urinary symptoms who also reported anal incontinence symptoms were included in the analysis. We collected patient demographics, electromyographic measurements, and responses to subjective questions about the status of their anal incontinence. Results Forty eight (55%) of 88 patients who started treatment completed the 8-visit protocol. No adverse events were reported. Mean age was 54.8 ± 12.0 years. There was a statistically significant increase in the mean maximal response comparing the first and final electromyographic measurements obtained during the first and last office visits: left side, 13.7 ± 9.3 μV versus 23.2 ± 13.5 μV, P
Source: Journal of Pelvic Medicine and Surgery - Category: Surgery Tags: Original Articles Source Type: research